The company offers multiple support services and resources for patients prescribed its products through Alnylam Assist®, designed to provide one-on-one support for patients and their healthcare teams ...

At Alnylam, we believe that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all," said Yvonne Greenstreet, M.D., Chief ...

An Alnylam spokesperson said the company was evaluating its options and may appeal. A BioNTech spokesperson said the filing "confirms Pfizer's and BioNTech's position that we do not infringe any ...

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of ...

Alnylam has also emphasized its commitment to patient access, with the majority of patients expected to pay $0 in out-of-pocket costs for AMVUTTRA, and multiple support programs in place to assist ...

The firm added that its Alnylam Assist program helps patients with insurance coverage and provides financial assistance, among other services. Cambridge, Massachusetts-based Alnylam said marketing ...

It represents a beacon of hope for our community.” Patients can find support and resources through Alnylam Assist. Amvuttra is covered for 99% of patients with hATTR-PN and most pay as little as $0 ...

Alnylam has a proven track record of working closely with payers to ensure broad patient access to our medicines, including pioneering innovative value-based agreements linked to clinical outcomes ...

− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality ...

Alnylam offers comprehensive patient support services through Alnylam Assist®, facilitating access to the treatment with the majority of patients expected to pay zero out-of-pocket costs.